25 results on '"Colin Dinney"'
Search Results
2. PD13-12 BLADDER SPARING TREATMENT IN PATIENTS WITH BCG UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER: AN ANALYSIS OF LONG-TERM SURVIVAL OUTCOMES
3. MP56-06 PATHOLOGIC DOWNSTAGING RATE AND PREDICTIVE BIOMARKER EXPLORATION IN PATIENTS WITH BIOPSY-PROVEN CLINICALLY NODE POSITIVE BLADDER CANCER UNDERGOING CHEMOTHERAPY FOLLOWED BY RADICAL CYSTECTOMY
4. PD25-06 COMBINATION TREATMENT WITH INTRAVESICAL INTERFERON GENE THERAPY AND PAN-ERBB RECEPTOR FAMILY BLOCKER IMPROVES SURVIVAL IN MICE WITH BLADDER CANCER
5. Data from miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy
6. Conflict of Interest Form 1 from miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy
7. PD12-03 INTERFERON α GENE THERAPY ALTERS TUMOR METABOLISM IN BLADDER CANCER
8. MP54-17 TIMING OF RADICAL CYSTECTOMY FOR BCG FAILURE
9. MP16-14 APIXABAN VERSUS ENOXAPARIN FOR POST-SURGICAL EXTENDED DURATION VTE PROPHYLAXIS: A PROSPECTIVE QUALITY IMPROVEMENT STUDY
10. PD12-02 PATIENT-DERIVED BLADDER TUMOR ORGANOIDS FOR INDIVIDUALIZED PRECLINICAL CHARACTERIZATION OF NADOFARAGENE FIRADENEOVEC INTERFERON GENE THERAPY
11. The origin of bladder cancer from mucosal field effects
12. Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma
13. The consensus molecular classification of muscle-invasive bladder cancer
14. The society of urologic oncology clinical trials consortium: A brief history and overview
15. MP58-03 DOSE DENSE MVAC PRIOR TO RADICAL CYSTECTOMY: A RETROSPECTIVE MULTI-INSTITUTIONAL EXPERIENCE
16. Immune modulation by combination type I interferon and checkpoint blockade therapy in murine urothelial carcinoma
17. Promising Efficacy & Safety in Trial for High-Grade BCG-Unresponsive NMIBC
18. Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNα/Syn3 treatment in a phase l study
19. Urinary nuclear matrix protein 22 (NMP22): A diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional-cell carcinoma of the bladder
20. The p63 protein isoform ΔNp63α inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205
21. POSITIVE SURGICAL MARGINS CONTRIBUTE TO DELAYED FAILURES IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR BLADDER CANCER
22. Direct cytotoxicity produced by adenoviral-mediated interferon α gene transfer in interferon-resistant cancer cells involves ER stress and caspase 4 activation
23. 490 PERIOPERATIVE OUTCOMES OF LAPAROSCOPIC RADICAL NEPHROURETERECTOMY AND REGIONAL LYMPHADENECTOMY IN PATIENTS WITH UPPER URINARY TRACT UROTHELIAL CARCINOMA AFTER NEOADJUVANT CHEMOTHERAPY
24. Abstract 5256: Mechanism of field cancerization
25. Bladder cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.